Price
No data yet.
Social Signal Score
Analyst Ratings
21 analystsRevenue
$1.42M-58.95%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Sean A. McCarthy
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 69
- Beta
- 2.14
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 1.88
Financials
Revenue
$1.42M-58.9%Net Income
$-20.67MEBITDA
$-20.31MFree Cash Flow
$-18.07MEPS (diluted)
$-0.09Shares Outstanding (diluted)
218.94M+502.7%Operating Expenses
$25.20MCash & Debt
$330.28MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $76.20M | $-17.37M | $-0.15 |
| 2024 | $138.10M | $31.87M | $0.38 |
| 2023 | $101.21M | $-569.0K | $-0.01 |
| 2022 | $53.16M | $-99.32M | $-1.48 |
| 2021 | $37.31M | $-115.87M | $-1.26 |
| 2020 | $68.43M | $-64.82M | $-0.71 |
| 2019 | $57.49M | $-102.24M | $-2.26 |
| 2018 | $59.50M | $-84.60M | $-2.03 |
| 2017 | $71.62M | $-43.10M | $-1.16 |
| 2016 | $15.04M | $-58.90M | $-1.63 |
| 2015 | $7.71M | $-35.37M | $-1.00 |
| 2014 | $5.08M | $-30.31M | $-0.87 |
| 2013 | $888.0K | $-15.14M | $-15.32 |
Valuation
CTMXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+100.00%Social Signal Score
Mentions (3)
- Newsseekingalpha.com·21d ago·Positive
CytomX Therapeutics, Inc. (CTMX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript CytomX Therapeutics, Inc. (CTMX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·35d ago·Neutral
CytomX Therapeutics to Present at Upcoming September Investor Conferences SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in September.
View source ↗ - Newsseekingalpha.com·54d ago·Negative
CytomX Therapeutics: Promising Varseta-M With Comfortable Runway CTMX has the PROBODY platform, which I think potentially unlocks difficult oncology targets by limiting drug activity in healthy tissue. Their lead asset is Varseta-M, which has interesting early colorectal cancer activity. Yet, it still requires larger and more mature datasets. CTMX's pipeline has lined up a Varseta-M monotherapy update, combination-study data, and new gastrointestinal cohorts. These are several catalysts through
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $-0.09 per share
Typical surprise +28.6% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.09 vs $-0.08miss
- Thu, May 7$-0.10 vs $-0.14beat
- Mon, Mar 16$-0.22 vs $-0.08miss
- Thu, Nov 6$-0.09 vs $-0.05miss
- Thu, Aug 7$-0.00 vs $-0.06beat
- Mon, May 12$0.27 vs $0.12beat
Estimates and results for CTMX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CTMX officers and directors.
- Bought
- —
- Sold
- $2.0m
0 trades
20 trades
- Ogden Christophersold
- Chu Yu-wayesold
- Mccarthy Sean A.sold
- Belvin Marciasold
- Ogden Christophersold
- Mccarthy Sean A.sold
- Ogden Christophersold
- Belvin Marciasold
80 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CTMX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.